Company news
Madrigal Pharmaceuticals, Inc. news in 2023
Madrigal Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
November 20, 2023
Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
November 9, 2023
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
November 9, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
November 5, 2023
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
September 27, 2023
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
September 12, 2023
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
September 10, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
August 7, 2023
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
July 16, 2023
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
June 29, 2023
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
June 21, 2023
Madrigal Pharmaceuticals Supports International NASH Day on June 8
June 5, 2023
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
May 31, 2023
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
May 10, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
May 8, 2023
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
April 17, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
February 22, 2023
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
January 5, 2023